Addyi (Flibanserin) in Adults 65 and Older: School, Work, and Daily Activity Considerations

What Is Flibanserin and Why Does Age Matter?

Flibanserin acts as a mixed serotonin 5-HT1A agonist and 5-HT2A antagonist with additional dopamine D4 activity in the prefrontal cortex. The FDA approved it in June 2015 under the brand name Addyi for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Use in postmenopausal or geriatric women is off-label, yet prescribing in this population occurs.

Age fundamentally changes how the body handles flibanserin. Hepatic CYP2C19 activity declines by roughly 30 to 40 percent between ages 20 and 70, which means older adults clear flibanserin more slowly and may reach higher steady-state plasma concentrations at the same 100 mg dose. The FDA prescribing information for Addyi explicitly flags that clinical trials did not enroll patients 65 and older, leaving a formal pharmacokinetic data gap for this age group.

Pharmacokinetics After 65

Reduced first-pass metabolism, lower plasma albumin (affecting protein binding), and decreased renal clearance of metabolites can all shift the effective exposure upward. A patient aged 70 taking flibanserin alongside a moderate CYP3A4 inhibitor, such as diltiazem or verapamil, both common in older adults, could see plasma area-under-the-curve values two to three times higher than what was studied in the key trials.

The three key trials (BEGONIA, VIOLET, and SNOWDROP) enrolled predominantly premenopausal women with a mean age in the mid-30s. SNOWDROP (N=949) reported a 0.5-unit improvement on the Female Sexual Function Index desire domain versus placebo over 24 weeks, a modest effect size that must be weighed against amplified CNS risk in older patients.

Why the Geriatric Gap Matters Clinically

No dedicated phase III data exist for adults 65 and older. Prescribers must extrapolate from younger trial populations while accounting for a physiologic profile, polypharmacy burden, and comorbidity pattern that differs substantially from the studied cohort. That mismatch is the central clinical tension for this age group.

CNS Depression and Cognitive Effects in Older Adults

The most clinically significant risk for an older adult taking flibanserin is CNS depression. Somnolence, sedation, and dizziness were reported in 11 percent, 9 percent, and 11 percent of flibanserin-treated participants in pooled trial data per the FDA label, compared with 4 percent, 3 percent, and 3 percent for placebo. These figures come from a younger, healthier population. The burden in older adults is likely higher.

Cognitive Safety Signals

CNS-depressant medications as a class affect processing speed, reaction time, and short-term memory. The 2023 American Geriatrics Society Beers Criteria includes several CNS-active agents in its list of drugs to use with caution or avoid in older adults specifically because of this profile. Flibanserin is not currently listed by name, but its pharmacodynamic mechanism places it in a category that warrants the same scrutiny.

A 2019 review in the British Journal of Clinical Pharmacology examining CNS drugs in older populations found that next-morning psychomotor impairment persisted beyond 8 hours in adults over 65 for drugs with similar half-lives to flibanserin (roughly 11 hours), compared with 4 to 5 hours in younger adults.

Impact on Cognitive Tasks: School and Continuing Education

Some adults 65 and older remain enrolled in community colleges, certificate programs, or professional continuing education. Flibanserin's next-morning sedation may reduce attention, recall, and testing performance. Patients attending early-morning classes, especially those requiring driving to campus, face a compounded risk from both the sedation itself and the FDA restriction on driving for 6 hours after each dose.

Practical guidance: schedule doses no later than 10 PM if a 7 AM class requires driving by 8 AM. That still leaves only a 9 to 10 hour buffer, and individual variation in clearance means some patients remain impaired longer. A dose-timing conversation with the prescriber is appropriate before any formal examination or skills assessment.

Fall Risk, Hypotension, and Physical Activity

Quantifying Fall Risk

Falls are the leading cause of injury-related death in adults 65 and older in the United States. The CDC reports that approximately 36 million falls occur annually in this age group, resulting in more than 32,000 deaths. Any drug that adds orthostatic hypotension or dizziness to this baseline is a serious concern.

CNS-depressant and antihypertensive drugs together are among the most studied contributors to fall risk. A meta-analysis in the BMJ (2018, N=79,081) found that sedative-hypnotic and CNS-active drugs increased fall-related fracture risk by approximately 47 percent in adults over 65, with the highest risk in the first 2 weeks of a new prescription.

Flibanserin's black-box warning specifically includes syncope. In the key trial safety pool, syncope was reported in 0.4 percent of flibanserin users versus 0.1 percent of placebo users. While these absolute numbers appear small, syncope in a 70-year-old carries very different consequences from syncope in a 35-year-old.

Exercise and Physical Activity Recommendations

Regular physical activity is one of the strongest evidence-based interventions for preserving sexual function, mood, and quality of life in older women. The 2018 Physical Activity Guidelines for Americans, Second Edition recommends 150 to 300 minutes of moderate-intensity aerobic activity per week for older adults, along with muscle-strengthening on 2 or more days.

These recommendations do not change because a patient is taking flibanserin. The timing and type of activity do.

Preferred activity windows and types:

• Morning exercise (6 to 12 hours after a bedtime dose) is lowest risk for most patients.
• Walking on flat, well-lit surfaces, swimming in a supervised setting, and chair-based resistance training carry less fall consequence than cycling outdoors or using step aerobics equipment.
• Yoga and balance training, which have demonstrated fall-prevention benefit per a Cochrane review (2019, 39 trials, N=2,860), are compatible with flibanserin use when scheduled during the low-sedation window.

Activities to Avoid Near Dose Time

Within the 6-hour post-dose window: driving, operating power tools, using ladders, swimming without direct supervision, and any activity requiring rapid balance correction (e.g., pickleball on uneven outdoor courts). Some patients will need a frank conversation with family members or care partners about these restrictions.

Alcohol: The Absolute Restriction

The FDA required a Risk Evaluation and Mitigation Strategy (REMS) program for flibanserin specifically because of the alcohol interaction. The REMS document states that patients must abstain from alcohol while taking flibanserin. A dedicated drug-interaction study showed that co-administration of flibanserin with alcohol produced clinically meaningful hypotension and syncope at a rate significantly higher than either substance alone, with effects observed at alcohol doses as low as two standard drinks.

In older adults, the ethanol interaction is compounded by two additional factors. First, hepatic alcohol dehydrogenase activity declines with age, so the same number of drinks produces a higher blood alcohol concentration. Second, age-related reductions in total body water increase peak alcohol concentration per drink. A two-drink exposure in a 70-year-old may produce the physiologic equivalent of three to three-and-a-half drinks in a 30-year-old.

Social settings common among older adults, including retirement community events, family dinners, and holiday gatherings, routinely include alcohol. Patients need direct counseling about this risk, including written guidance from their prescriber. The REMS program requires prescribers to confirm alcohol counseling has occurred before dispensing.

A practical screening framework for older adults before initiating flibanserin:

1. Document all CNS-active medications (opioids, benzodiazepines, sleep aids, antihistamines, antidepressants) and assess additive sedation burden.
2. Assess fall history: any fall in the prior 12 months is a relative contraindication to adding another CNS-active agent without a formal geriatric risk-benefit review.
3. Screen for hepatic impairment: flibanserin is contraindicated in any degree of hepatic impairment per FDA labeling because AUC increases by up to 4.5-fold in moderate impairment.
4. Confirm absolute alcohol cessation ability. If the patient reports regular social drinking and is unwilling to stop, flibanserin should not be prescribed.
5. Review CYP3A4 and CYP2C19 inhibitor exposure: diltiazem, fluconazole, clarithromycin, and omeprazole (a common CYP2C19 inhibitor in older adults) all raise flibanserin levels.
6. Establish a 4-week follow-up visit specifically to assess next-morning sedation, orthostasis, and any falls or near-falls.

Driving, Transportation, and Community Mobility

The FDA label states: "Instruct patients to avoid activities that require complete mental alertness, such as driving, operating hazardous machinery until the next day following a nighttime dose." For older adults, this restriction has practical consequences that extend beyond the obvious.

Driving Cessation and Isolation Risk

Older adults who self-restrict driving due to medication side effects risk social isolation, a condition linked independently to cognitive decline and depression. A JAMA Internal Medicine study (2019, N=4,777) found that driving cessation in older adults was associated with a near-doubling of depressive symptoms within 2 years. Prescribers should assess whether a patient's social infrastructure can accommodate a next-morning driving restriction before initiating flibanserin.

If a patient relies on personal driving for morning medical appointments, grocery runs, or community programs, a nighttime sedating drug that impairs 6 to 8 hours of next-day function may produce a net reduction in quality of life that offsets any benefit to sexual desire.

Alternatives for Geriatric Patients With HSDD

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction notes that non-pharmacologic approaches, including cognitive behavioral therapy and mindfulness-based sex therapy, have demonstrated efficacy for HSDD and carry no sedation burden. These should be part of any treatment conversation with an older patient before or alongside flibanserin.

Bremelanotide (Vyleesi), a subcutaneous melanocortin receptor agonist approved in 2019 for premenopausal HSDD, has a different mechanism and does not carry the same CNS depression profile, though nausea and transient blood pressure elevation are concerns and it is equally off-label in postmenopausal and geriatric women.

Polypharmacy and Drug Interactions Specific to Older Adults

Adults 65 and older take an average of 4.5 prescription medications daily according to CDC National Health Statistics data. At 5 or more concurrent medications, drug-drug interaction probability exceeds 50 percent.

CYP2C19 and CYP3A4 Interactions

Flibanserin is primarily metabolized by CYP3A4 and secondarily by CYP2C19. Drugs that inhibit these enzymes are common in older adults.

| Interacting Drug | Mechanism | Effect on Flibanserin Exposure | |---|---|---| | Fluconazole 200 mg | Strong CYP3A4 inhibitor | AUC increase up to 7-fold | | Clarithromycin | Strong CYP3A4 inhibitor | AUC increase up to 3-fold | | Diltiazem 240 mg | Moderate CYP3A4 inhibitor | AUC increase approximately 2-fold | | Omeprazole | Moderate CYP2C19 inhibitor | Modest AUC increase | | Fluoxetine | Moderate CYP2C19 and CYP3A4 inhibitor | AUC increase approximately 1.5-fold |

All of these interactions are described in the Addyi FDA prescribing information. Fluconazole co-administration is a labeled contraindication. Diltiazem and fluoxetine are not contraindicated but do require a careful risk-benefit assessment.

Serotonin Syndrome Risk

Flibanserin's 5-HT1A agonist activity creates a theoretical serotonin syndrome risk when combined with SSRIs, SNRIs, or triptans. While the published case evidence for flibanserin-specific serotonin syndrome is limited, the mechanistic concern is real. Older adults with depression or migraine may already be taking one or more serotonergic agents. This warrants a formal medication reconciliation before prescribing.

Monitoring Schedule and Red Flags for Older Patients

The following monitoring schedule is consistent with both FDA labeling and the principles of the American Geriatrics Society's framework for medication safety in older adults.

Baseline (before first dose):

• Orthostatic blood pressure measurement (lying to standing, 1 and 3 minutes)
• Fall risk screen using the validated 4-item Falls Risk Assessment Tool or Timed Up and Go test
• Complete medication reconciliation with focus on CYP3A4/CYP2C19 inhibitors
• Liver function tests if hepatic disease history exists
• Explicit written and verbal alcohol cessation counseling (required by REMS)

4-week follow-up:

• Repeat orthostatic BP
• Ask specifically about near-falls, dizziness on rising, or daytime sedation affecting activities
• Assess whether morning driving or activity restrictions have created social or functional problems

12-week decision point:

• If no meaningful improvement in desire scores on a validated tool such as the Female Sexual Function Index, strong consideration should be given to discontinuation per Endocrine Society guidance, which states benefit should be apparent within 8 weeks.

Discontinue immediately if:

• Any syncopal episode occurs
• Fall with injury occurs
• New moderate or severe hepatic disease is diagnosed
• Patient is unable to maintain alcohol abstinence

Special Situations: Assisted Living and Long-Term Care Settings

Patients in assisted living or skilled nursing facilities take flibanserin in a supervised context. Several issues become specific to that setting.

Nighttime medication administration rounds may not align with the 10 PM bedtime dosing recommended to maximize overnight clearance. A dose given at midnight increases next-morning sedation at the 6 AM breakfast period, raising aspiration and fall risk. Prescribers working with facility pharmacists should ensure dose timing is explicitly documented in the medication administration record.

Cognitive status assessments such as the Montreal Cognitive Assessment (MoCA) or Mini-Mental State Examination (MMSE) may yield artificially lower scores if administered within 8 hours of a flibanserin dose due to residual sedation. Clinicians and facilities should standardize assessment timing to at least 10 hours post-dose.

Staff education matters. A nursing aide unfamiliar with flibanserin's sedation profile may not flag a patient's slowed gait as drug-related. Facility in-service materials should include flibanserin by name on lists of CNS-active medications requiring gait monitoring.

Patient Counseling Points Summarized

• Take flibanserin at bedtime. Taking it any other time of day increases sedation during waking hours and is explicitly addressed in the FDA label.
• Do not drive until at least 6 hours after each dose, and only if you feel fully alert.
• Zero alcohol. Not one glass with dinner. The hypotensive interaction is real and potentially life-threatening in your age group.
• Tell every other prescriber and pharmacist you are taking this medication. CYP3A4 inhibitors, including common antifungals and antibiotics, can sharply raise your dose exposure.
• If you feel dizzy when standing up, sit back down immediately and call your prescriber before taking the next dose.
• Report any fainting, near-fainting, or unexplained falls to your prescriber right away.
• If you see no improvement in sexual desire within 8 weeks, discuss stopping the medication. Continuing an ineffective sedating drug carries risk without benefit.

Bedtime dosing, confirmed by a pharmacokinetic study cited in the FDA label showing peak plasma concentration at approximately 45 minutes post-dose, is the single most important daily activity modification for any patient taking flibanserin, and especially for adults 65 and older.